Structural Basis for HCAR3 Agonist Selectivity in Lipid Meta

2026-04-29

Structural Insights into HCAR3 Agonist Selectivity: Implications for Lipid Metabolism Research

Study Background and Research Question

Hydroxycarboxylic acid receptors (HCARs), particularly HCAR2 (also known as GPR109A) and HCAR3 (GPR109B), are metabolite-sensing G-protein coupled receptors (GPCRs) that play pivotal roles in lipid metabolism and are promising targets for treating dyslipidemia and metabolic disorders. While HCAR2-targeted agonists have been clinically explored, their use is limited by adverse effects such as cutaneous flushing. In contrast, the physiological and structural basis underlying HCAR3 activation, and how it differs in ligand recognition and selectivity from HCAR2, remain less well understood. The present study by Ye et al. (2025) addresses this gap by providing high-resolution structural and functional data for HCAR3 in complex with selective agonists, including (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid, known as Acifran (paper).

Key Innovation from the Reference Study

The central innovation of this research lies in the use of single-particle cryo-electron microscopy (cryo-EM) to resolve, at near-atomic resolution, the three-dimensional structures of HCAR3 in complex with four different agonists: compound 6O, D-phenyllactic acid, IBC293, and Acifran. The team also presents the structure of HCAR2 bound to Acifran. This approach directly elucidates the conformational states associated with agonist binding and uncovers the molecular interactions dictating ligand selectivity. Notably, the study demonstrates that ligand selectivity between HCAR3 and HCAR2 is governed by specific residue differences in the orthosteric binding pocket, with implications for rational drug design targeting lipid metabolism regulation (paper).

Methods and Experimental Design Insights

The research team expressed HCAR3-Gi and HCAR2-Gi complexes in Sf9 insect cells and purified these receptor–G protein assemblies for structural analysis. Using cryo-EM, they obtained density maps at resolutions of 3.05–3.31 Å for HCAR3-agonist complexes and 2.72 Å for the HCAR2-Acifran complex. Complementary cAMP inhibition assays in HEK-293 cells were performed to functionally validate the ligand–receptor interactions observed structurally. The combined structural and biochemical approach enabled detailed mapping of the orthosteric binding pocket and identification of key residues responsible for ligand recognition and receptor specificity (paper).

Protocol Parameters

assay | cryo-EM structure determination | 2.72–3.31 Å resolution | Enables visualization of ligand–receptor interactions at near-atomic detail | paper
assay | cAMP inhibition assay | HEK-293 cells | Validates functional agonist activity and selectivity | paper
compound storage | -20°C | Preserves compound stability for short-term experiments | workflow_recommendation
compound solubility | <21.82 mg/ml in ethanol/DMSO | Ensures appropriate dosing in in vitro assays | product_spec

Core Findings and Why They Matter

The study’s structural analyses reveal that the highest affinity agonist for HCAR3, compound 6O, fully occupies both R1 and R2 regions of the orthosteric site, unlike other agonists. Acifran, as a selective agonist for both HCAR3 and HCAR2, enables direct structural comparison of ligand binding across the two receptors. The authors identify the critical role of π–π stacking interactions with residue F107 (3.32) in HCAR3 (corresponding to L107 in HCAR2), as well as pocket size differences resulting from variations at V/L83 (2.60), Y/N86 (2.63), and S/W91 (2.48), in dictating ligand selectivity (paper). These findings provide a molecular rationale for developing HCAR3-specific agonists that may avoid the adverse effects linked to HCAR2 activation, such as skin flushing. From a translational perspective, this work advances the understanding of how hypolipidemic agents for lipid metabolism research, such as Acifran, engage their target receptors. It also offers a structural template for designing new compounds with improved selectivity and safety profiles.

Comparison with Existing Internal Articles

Internal resources, such as "Structural Basis of HCAR3 Agonist Selectivity: Insights from Cryo-EM," provide accessible overviews of how cryo-EM advances our understanding of receptor–ligand interactions (internal). However, the reference study stands out by delivering the experimental atomic models and directly linking structure to function through biochemical validation. Other resources (e.g., "Acifran: A Precision Hypolipidemic Agent for Lipid Metabo..." and "Acifran: Selective HM74A/GPR109A Agonist for Lipid Metabo...") focus on experimental workflows and the utility of Acifran in lipid signaling pathway modulation, but they rely on previously published or modeled receptor structures (internal; internal). The present study contributes direct, high-resolution structural evidence, bridging the gap between empirical research and rational ligand design.

Limitations and Transferability

While the study provides comprehensive structural and functional insights, it is primarily limited to in vitro systems, with receptor expression in insect and human cell lines. The structures represent receptor–G protein complexes in the presence of agonists but do not capture the full dynamic range of receptor conformations or downstream signaling in physiological contexts. Additionally, ligand selectivity findings, though robust at the molecular level, require further validation in animal models or clinical settings to confirm translational relevance. The transferability of these insights to other GPCRs or unrelated metabolic pathways is not established within the current evidence base (paper).

Research Support Resources

To facilitate studies on lipid metabolism regulation and ligand–receptor interactions, researchers can utilize Acifran (SKU B6848), a rigorously characterized hypolipidemic agent for lipid metabolism research and a selective HM74A/GPR109A and GPR109B agonist. Acifran’s established utility in receptor-ligand assays and lipid signaling pathway modulation aligns with the protocols and findings detailed in the reference study (workflow_recommendation; product_spec). For further experimental design guidance and troubleshooting, related articles detail optimized usage scenarios and data interpretation strategies, supporting robust outcomes in metabolic disorder research.